Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback